2025 Q4 -tulosraportti
Vain PDF
27 päivää sitten
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 17 481 | - | - | ||
| 1 | - | - | ||
| 5 665 | - | - | ||
| 4 378 | - | - | ||
| 11 810 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 24.6. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 | ||
2024 Q4 -tulosraportti 26.3.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·11 t sittenThe technical picture in SoftOx Solutions seems to me to be pointing straight down again. Extensive market manipulation not only on Euronext Growth, but also all the way into XOSL, we can thank for that. The trends we previously had are broken and the movements make little sense. There's no point in trying to fight against the algorithms on low volume. There are also very few who dare to accumulate long-term anymore. To me, the situation looks like no small-cap stocks are safe in a short-term perspective until those responsible for the market start doing their job. For those of you trading with an IKZ account, a good start is to opt out of lending shares for shorting. Then you at least don't give the short sellers free ammunition.
·8 t sittenIf manipulation is behind the price movements in Softox with spoofing and aggressive shorting, you have a serious problem on the Oslo Stock Exchange. It reminds too much of parts of smallcap in the USA which has become almost impossible to invest in. Hedge funds and other big players control the price exactly in the direction they want. If the Norwegian Financial Supervisory Authority doesn't put its foot down, it will soon be a thieves' market in Oslo and then stock trading will be a constant "loosing game" for ordinary small investors.
·8 t sittenYes, it was about an investor last week who has been sentenced twice for this. He received a total fine of 5 mill NOK. The yo-yo price started then. It is very annoying and impossible to predict the development. But as DrEvil above writes. Softox will probably give a very good return the day they have a finished result, which I believe they will get. Then we can collect a nice sum. So we'll have to see this through for now.
·11 t sittenNew article with Thomas Bjarnsholt as co-author is, in my assessment, relevant for the SoftOx case. The article describes how current treatments can significantly reduce the bacterial load in chronic lung infections, but not necessarily eliminate the remaining bacteria, which can instead survive in biofilms. It is precisely biofilms that make bacteria difficult for both the immune system and antibiotics to remove. This supports that there continues to be a treatment gap, and it is precisely here that SIS-03 could potentially play a role, if the product clinically proves capable of breaking down biofilms in the lungs. What's also interesting is that the study was conducted at Rigshospitalet. The same environment where the SIS-03 study is running. The article alone does not change the case, but in my opinion, it strengthens the biological logic behind what SoftOx is trying to solve. Link to the article: https://pmc.ncbi.nlm.nih.gov/articles/PMC13083049/·4 min sittenI have received a summary and possible link to SoftOx's research from this article. Chatgpt: Here is a simple explanation + what it can mean in practice – and a link to SoftOx Solutions: ⸻ 🔬 Short summary The study looks at the bacterium Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. It exists in two forms: * Biofilm = clumps/"slime layer" of bacteria (difficult to kill) * Planktonic = single bacteria (more "free") The body's immune system (neutrophil cells) attacks the bacteria by creating reactive oxygen species (ROS) → this is called oxidative burst. ⸻ 🧠 Main findings – very simply explained * At low amounts of bacteria: * Biofilm causes a stronger immune reaction * → more inflammation and tissue damage * At high amounts of bacteria: * Free bacteria cause the strongest response 👉 In other words: Not just how many bacteria you have, but how they are organized, determines how much damage occurs. ⸻ ⚠️ Important insight * Biofilm can be extra dangerous even in small amounts * The immune system can damage the lungs more than the bacteria themselves * This can explain why patients don't get much better even if the bacterial load decreases ⸻ 🔗 Relevance to SoftOx Solutions SoftOx works with: * Disinfection / treatment of infections * Focus on biofilm-related problems (especially wounds) Potential connection: 1. Biofilm is the main problem * The study confirms that biofilm: * is difficult to treat * can trigger strong inflammation even in small amounts 👉 This is exactly the area SoftOx targets 2. Breaking down biofilm = key * If SoftOx technology: * dissolves biofilm * kills bacteria more effectively → can reduce both infection and inflammation 3. Not just killing bacteria – but reducing damage * Important point in the study: * The immune response (ROS) causes tissue damage 👉 If SoftOx also reduces biofilm-trigger → it can provide clinically better effect than antibiotics alone 4. Relevant also outside the lungs * The study also mentions: * chronic wounds 👉 This is directly within SoftOx's main area ⸻ 🧩 A bit of an "investor angle" The study strengthens the following thesis: * The market is moving towards biofilm-targeting treatments * Classic antibiotics are not enough * Solutions that: * break down biofilm * reduce inflammation can become very important ⸻ 🧭 Bottom line * Biofilm is not just difficult to kill – it can cause more damage at low bacterial loads * Controlling biofilm can be just as important as reducing bacteria * This indirectly supports the case for companies like SoftOx Solutions
·17 t sittenNot long until it explodes. Just buy up the 0.12 resistance and join the ride.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
27 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11 t sittenThe technical picture in SoftOx Solutions seems to me to be pointing straight down again. Extensive market manipulation not only on Euronext Growth, but also all the way into XOSL, we can thank for that. The trends we previously had are broken and the movements make little sense. There's no point in trying to fight against the algorithms on low volume. There are also very few who dare to accumulate long-term anymore. To me, the situation looks like no small-cap stocks are safe in a short-term perspective until those responsible for the market start doing their job. For those of you trading with an IKZ account, a good start is to opt out of lending shares for shorting. Then you at least don't give the short sellers free ammunition.·8 t sittenIf manipulation is behind the price movements in Softox with spoofing and aggressive shorting, you have a serious problem on the Oslo Stock Exchange. It reminds too much of parts of smallcap in the USA which has become almost impossible to invest in. Hedge funds and other big players control the price exactly in the direction they want. If the Norwegian Financial Supervisory Authority doesn't put its foot down, it will soon be a thieves' market in Oslo and then stock trading will be a constant "loosing game" for ordinary small investors.·8 t sittenYes, it was about an investor last week who has been sentenced twice for this. He received a total fine of 5 mill NOK. The yo-yo price started then. It is very annoying and impossible to predict the development. But as DrEvil above writes. Softox will probably give a very good return the day they have a finished result, which I believe they will get. Then we can collect a nice sum. So we'll have to see this through for now.
- ·11 t sittenNew article with Thomas Bjarnsholt as co-author is, in my assessment, relevant for the SoftOx case. The article describes how current treatments can significantly reduce the bacterial load in chronic lung infections, but not necessarily eliminate the remaining bacteria, which can instead survive in biofilms. It is precisely biofilms that make bacteria difficult for both the immune system and antibiotics to remove. This supports that there continues to be a treatment gap, and it is precisely here that SIS-03 could potentially play a role, if the product clinically proves capable of breaking down biofilms in the lungs. What's also interesting is that the study was conducted at Rigshospitalet. The same environment where the SIS-03 study is running. The article alone does not change the case, but in my opinion, it strengthens the biological logic behind what SoftOx is trying to solve. Link to the article: https://pmc.ncbi.nlm.nih.gov/articles/PMC13083049/·4 min sittenI have received a summary and possible link to SoftOx's research from this article. Chatgpt: Here is a simple explanation + what it can mean in practice – and a link to SoftOx Solutions: ⸻ 🔬 Short summary The study looks at the bacterium Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. It exists in two forms: * Biofilm = clumps/"slime layer" of bacteria (difficult to kill) * Planktonic = single bacteria (more "free") The body's immune system (neutrophil cells) attacks the bacteria by creating reactive oxygen species (ROS) → this is called oxidative burst. ⸻ 🧠 Main findings – very simply explained * At low amounts of bacteria: * Biofilm causes a stronger immune reaction * → more inflammation and tissue damage * At high amounts of bacteria: * Free bacteria cause the strongest response 👉 In other words: Not just how many bacteria you have, but how they are organized, determines how much damage occurs. ⸻ ⚠️ Important insight * Biofilm can be extra dangerous even in small amounts * The immune system can damage the lungs more than the bacteria themselves * This can explain why patients don't get much better even if the bacterial load decreases ⸻ 🔗 Relevance to SoftOx Solutions SoftOx works with: * Disinfection / treatment of infections * Focus on biofilm-related problems (especially wounds) Potential connection: 1. Biofilm is the main problem * The study confirms that biofilm: * is difficult to treat * can trigger strong inflammation even in small amounts 👉 This is exactly the area SoftOx targets 2. Breaking down biofilm = key * If SoftOx technology: * dissolves biofilm * kills bacteria more effectively → can reduce both infection and inflammation 3. Not just killing bacteria – but reducing damage * Important point in the study: * The immune response (ROS) causes tissue damage 👉 If SoftOx also reduces biofilm-trigger → it can provide clinically better effect than antibiotics alone 4. Relevant also outside the lungs * The study also mentions: * chronic wounds 👉 This is directly within SoftOx's main area ⸻ 🧩 A bit of an "investor angle" The study strengthens the following thesis: * The market is moving towards biofilm-targeting treatments * Classic antibiotics are not enough * Solutions that: * break down biofilm * reduce inflammation can become very important ⸻ 🧭 Bottom line * Biofilm is not just difficult to kill – it can cause more damage at low bacterial loads * Controlling biofilm can be just as important as reducing bacteria * This indirectly supports the case for companies like SoftOx Solutions
- ·17 t sittenNot long until it explodes. Just buy up the 0.12 resistance and join the ride.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 17 481 | - | - | ||
| 1 | - | - | ||
| 5 665 | - | - | ||
| 4 378 | - | - | ||
| 11 810 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 24.6. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 | ||
2024 Q4 -tulosraportti 26.3.2025 |
2025 Q4 -tulosraportti
Vain PDF
27 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 24.6. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 | ||
2024 Q4 -tulosraportti 26.3.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11 t sittenThe technical picture in SoftOx Solutions seems to me to be pointing straight down again. Extensive market manipulation not only on Euronext Growth, but also all the way into XOSL, we can thank for that. The trends we previously had are broken and the movements make little sense. There's no point in trying to fight against the algorithms on low volume. There are also very few who dare to accumulate long-term anymore. To me, the situation looks like no small-cap stocks are safe in a short-term perspective until those responsible for the market start doing their job. For those of you trading with an IKZ account, a good start is to opt out of lending shares for shorting. Then you at least don't give the short sellers free ammunition.·8 t sittenIf manipulation is behind the price movements in Softox with spoofing and aggressive shorting, you have a serious problem on the Oslo Stock Exchange. It reminds too much of parts of smallcap in the USA which has become almost impossible to invest in. Hedge funds and other big players control the price exactly in the direction they want. If the Norwegian Financial Supervisory Authority doesn't put its foot down, it will soon be a thieves' market in Oslo and then stock trading will be a constant "loosing game" for ordinary small investors.·8 t sittenYes, it was about an investor last week who has been sentenced twice for this. He received a total fine of 5 mill NOK. The yo-yo price started then. It is very annoying and impossible to predict the development. But as DrEvil above writes. Softox will probably give a very good return the day they have a finished result, which I believe they will get. Then we can collect a nice sum. So we'll have to see this through for now.
- ·11 t sittenNew article with Thomas Bjarnsholt as co-author is, in my assessment, relevant for the SoftOx case. The article describes how current treatments can significantly reduce the bacterial load in chronic lung infections, but not necessarily eliminate the remaining bacteria, which can instead survive in biofilms. It is precisely biofilms that make bacteria difficult for both the immune system and antibiotics to remove. This supports that there continues to be a treatment gap, and it is precisely here that SIS-03 could potentially play a role, if the product clinically proves capable of breaking down biofilms in the lungs. What's also interesting is that the study was conducted at Rigshospitalet. The same environment where the SIS-03 study is running. The article alone does not change the case, but in my opinion, it strengthens the biological logic behind what SoftOx is trying to solve. Link to the article: https://pmc.ncbi.nlm.nih.gov/articles/PMC13083049/·4 min sittenI have received a summary and possible link to SoftOx's research from this article. Chatgpt: Here is a simple explanation + what it can mean in practice – and a link to SoftOx Solutions: ⸻ 🔬 Short summary The study looks at the bacterium Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. It exists in two forms: * Biofilm = clumps/"slime layer" of bacteria (difficult to kill) * Planktonic = single bacteria (more "free") The body's immune system (neutrophil cells) attacks the bacteria by creating reactive oxygen species (ROS) → this is called oxidative burst. ⸻ 🧠 Main findings – very simply explained * At low amounts of bacteria: * Biofilm causes a stronger immune reaction * → more inflammation and tissue damage * At high amounts of bacteria: * Free bacteria cause the strongest response 👉 In other words: Not just how many bacteria you have, but how they are organized, determines how much damage occurs. ⸻ ⚠️ Important insight * Biofilm can be extra dangerous even in small amounts * The immune system can damage the lungs more than the bacteria themselves * This can explain why patients don't get much better even if the bacterial load decreases ⸻ 🔗 Relevance to SoftOx Solutions SoftOx works with: * Disinfection / treatment of infections * Focus on biofilm-related problems (especially wounds) Potential connection: 1. Biofilm is the main problem * The study confirms that biofilm: * is difficult to treat * can trigger strong inflammation even in small amounts 👉 This is exactly the area SoftOx targets 2. Breaking down biofilm = key * If SoftOx technology: * dissolves biofilm * kills bacteria more effectively → can reduce both infection and inflammation 3. Not just killing bacteria – but reducing damage * Important point in the study: * The immune response (ROS) causes tissue damage 👉 If SoftOx also reduces biofilm-trigger → it can provide clinically better effect than antibiotics alone 4. Relevant also outside the lungs * The study also mentions: * chronic wounds 👉 This is directly within SoftOx's main area ⸻ 🧩 A bit of an "investor angle" The study strengthens the following thesis: * The market is moving towards biofilm-targeting treatments * Classic antibiotics are not enough * Solutions that: * break down biofilm * reduce inflammation can become very important ⸻ 🧭 Bottom line * Biofilm is not just difficult to kill – it can cause more damage at low bacterial loads * Controlling biofilm can be just as important as reducing bacteria * This indirectly supports the case for companies like SoftOx Solutions
- ·17 t sittenNot long until it explodes. Just buy up the 0.12 resistance and join the ride.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 17 481 | - | - | ||
| 1 | - | - | ||
| 5 665 | - | - | ||
| 4 378 | - | - | ||
| 11 810 | - | - |
Välittäjätilasto
Dataa ei löytynyt